TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Gastroesophageal Reflux Treatment in Scleroderma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Phase 1 SSc patients who fit all inclusion and exclusion criteria will be eligible to phase 1 study for evaluation the prevalence of omeprazole resistant-GERD~Inclusion criteria:~1. SSc patients aged between 18 and 65 years.~2. Clinically diagnosed as GERD and GERD-questionnaire score \>3~3. Must not receive any proton pump inhibitor (PPI) or prokinetic drug within 2 weeks before baseline evaluation~Exclusion criteria:~1. Pregnancy or lactation~2. Previous history of gastroesophageal surgery or endoscopic therapy due to severe erosive esophagitis~3. Present of Barrett's esophagus~4. Bedridden and confined to no self-care~5. Evidence of active malignant disease~6. Present of uncontrolled or severe medical problems such as asthma, angina, hepatic or renal diseases~7. Present of active infection that needs systemic antibiotic~8. Allergic history of omeprazole~9. Receiving prohibit co-medications that may have drug interaction or attenuate GERD symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate~Phase 2 randomized parallel study SSc patients who fit all inclusion and exclusion criteria will be eligible to phase 2 study.~Inclusion criteria:~1. SSc patients who completed the phase 1 study.~2. The subjects were defined as PPI-resistance.~3. The subject must be willing to continue phase 2 study.~Exclusion criteria:~1. Pregnancy~2. Present of uncontrolled or severe medical problems~3. Present of active infection~4. Allergic history of alginic acid or domperidone~5. Receiving prohibit co-medications that may have drug interaction or attenuate GERD symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate~6. Chewing difficulty

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Omeprazole plus alginic acid and placebo of domperidone (Type: EXPERIMENTAL): None
- Omeprazole plus domperidone and placebo of alginic acid (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Reduction of Lopinavir in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 2- 18 years old~* Documented positive test for HIV-1 infection~* PI-naïve~* HIV RNA viral load \> 1,000 copies~* Written informed consent~Exclusion Criteria:~* Active opportunistic infection~* Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion.~* Use of concomitant medication that may interfere with the pharmacokinetics of lopinavir/ritonavir~* Pregnancy or lactating~* Inability to understand the nature and extent of the study and the procedures required.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Lopinavir/ritonavir standard dose + zidovudine and lamivudine
- 2 (Type: ACTIVE_COMPARATOR): Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated BCR-ABL-positive ALL~* Age between 15 and 64 years~* Performance status between 0 and 3 (ECOG criteria)~* Adequate functioning of the liver (serum bilirubin level \< 2.0 mg/dL), kidneys (serum creatinine level \< 2.0 mg/dL), and heart (left ventricular ejection fraction greater than 50% and no severe abnormalities detected on electrocardiograms and echocardiographs)~* Written informed consent to participate in the trial~Exclusion Criteria:~* Uncontrolled active infection~* Another severe and/or life-threatening disease~* Positive for HIV antibody and/or hepatitis B surface (HBs) antigen tests~* Another primary malignancy which is clinically active and/or requires medical interventions~* Pregnant and/or lactating women~* Past history of renal failure

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Active axial spondyloarthritis with disease duration ≤5 years, and chronic back pain of ≥3 month duration~* Have either an inadequate response to 30 days of optimal daily doses of at least one non-steroidal anti-inflammatory drug (NSAID) or must be unable to receive a full 30 day maximal NSAID therapy because of intolerance, toxicity or contraindications to NSAIDs~* Females of child-bearing potential must use contraception~* No history of untreated latent or active tuberculosis~Exclusion Criteria:~* Fulfillment of modified New York criteria for ankylosing spondylitis~* Has ever received tumor necrosis factor (TNF)-α targeted therapy or any biological agents~* Any systemic inflammatory condition other than spondyloarthritis~* Serious infection within 2 months~* Any known malignancy or a history of malignancy within the previous 5 years~* Has or had a substance abuse (drug or alcohol) problem within the previous 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Golimumab→Golimumab (Type: EXPERIMENTAL): In Part 1, participants receive golimumab 50 mg, administered subcutaneously (SC) every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 48 weeks treatment with golimumab.)
- Placebo→Golimumab (Type: PLACEBO_COMPARATOR): In Part 1, participants receive placebo, administered SC every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 32 weeks treatment with golimumab.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must provide written informed consent~* Patients must be at least 16 years old~* Patients must have a current diagnosis of Fabry disease and have a clinical presentation consistent of Fabry disease (decreased sweating, Fabry pain, angiokeratoma, etc.)~* Patients may not have received enzyme replacement therapy as a treatment for Fabry disease~* Patients must have a documented plasma a-galactosidase A (aGAL) activity of \< 1.5 nmol/hr/mL or a documented leukocyte aGAL activity of \< 4 nmol/hr/mg~* Patients must have one or more of the following: a serum creatinine measurement of 1.2 to 3 mg/dL (106.1 to 265 umol/L) OR estimated creatinine clearance \< 80 mL/min only if the patient's serum creatinine measurement is \< 1.2 mg/dL~* Female patients of childbearing potential must have a negative pregnancy test prior to each dosing and all female patients must use a medically accepted form of contraception~Exclusion Criteria:~* Patient has undergone or is currently scheduled for kidney transplantation or is currently on dialysis~* Patient has acute renal failure~* Patient has participated in a study employing an investigational drug within 30 days of study entry~* Patient has diabetes mellitus or presence of confounding renal disease~* Patient has a history of transient ischemic attack (TIA) or ischemic stroke within 3 months of study entry documented by mild-to-moderate neurological deficit~* Patient has critical coronary disease~* Patient has congestive heart failure~* Patient has severe residual neurological deficit that will confound the detection of new events as determined by an attending neurologist and/or Principal Investigator~* Patient is unwilling to comply with the requirements of the protocol or the patient has a medical condition, serious intercurrent illness, or extenuating circumstances that would significantly decrease study compliance, including prescribed follow-up

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients randomized to placebo
- Fabrazyme (agalsidase beta) (Type: ACTIVE_COMPARATOR): Patients randomized to Fabrazyme (agalsidase beta).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Megestrol Acetate in Severe Chronic Obstructive Pulmonary Disease With Loss of Weight

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnose of COPD (criteria ATS/ERS 2004)~* Clinical stability more than 3 months~* Smokers or ex-smokers of more than \> 10 boxes/year than do not modify their smoking habit during the study.~* FEV1 (post-bronchodilator) \< 50%. FEV1/FVC ≤ 70~* Negative answer to bronchodilator(≤ 20% del FEV1 o ≤ 200 ml.after 400 mcg.de salbutamol inhaled)~* BMI \< 21 Kg/m2 ó BMI 21-25 Kg/m with loss weight of 5% of the habitual body weight in the last 3 months, without other reason that could explain it independently of the COPD.~Exclusion Criteria:~* Use of nasogastric catheter~* Concomitant treatment with steroid, anabolics or other progestagens.~* Loss of body weight related with other causes: hyperthyroidism, enteral malnutrition ( Crohn disease...), neoplasias,etc~* Treatment with Megestrol Acetate in the last 6 months

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Megestrol acetate: sachets of granulated 160 mg. Dose: 160 mg/b.i.d. Duration 8 weeks
- 2 (Type: PLACEBO_COMPARATOR): The placebo is the excipient of the experimental drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV)~* Patients currently treated with oral risperidone, olanzapine or a conventional neuroleptic monotherapy at doses not exceeding 6 mg risperdal, 20 mg olanzapine, or a conversion dose of 10 mg haloperidol for oral conventional agents~* Patients who are stable (judged clinically stable by the investigator and on a stable dose of medication for 4 weeks or longer) but not optimally treated (non-satisfactory treatment regarding symptoms or adverse events)~Exclusion Criteria:~* Diagnosis other than schizophrenia or schizoaffective disorder by DSM-IV Axis I criteria~* Patients being treated with antipsychotic agents other than oral risperidone, olanzapine or conventional oral neuroleptic agents~* Patients with known hypersensitivity to oral risperidone, quetiapine, aripiprazole, or who are known non-responders to oral risperidone, quetiapine, aripiprazole or to previous treatment with at least 2 antipsychotic agents~* Patients treated with mood stabilizers or antidepressants who are not on stable dose for at least 3 months before study initiation~* Pregnant or nursing females, or those lacking adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Risperidone Long Acting Injectable (LAI) 25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
- 002 (Type: ACTIVE_COMPARATOR): Quetiapine Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
- 003 (Type: OTHER): Aripiprazole 10-30 mg oral once daily for 104 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adhesion of Lidocaine Topical System 1.8%

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must be healthy based on by medical history, laboratory work, and physical exam~* Be at least 18 years of age~* If childbearing potential, use of acceptable form of birth control~* In the case of females of childbearing potential, have a negative serum pregnancy test~Key Exclusion Criteria:~* Allergy or known hypersensitivity to lidocaine, amide-type local anesthetics, or any component of the product formulation~* Any major medical illness 3 months prior or any significant history or ongoing chronic medical illness~* Subjects with conditions that might affect application of the product or its adhesive properties (including psoriasis, eczema, atopic dermatitis, damaged or irritated epidermal layer, and excessive hair or oil on the skin)~* History of addiction, abuse, and misuse of any drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lidocaine Patch (Type: EXPERIMENTAL): All subjects received one lidocaine topical system, which was applied to a predetermined fixed area on subject's left side of the back or right side of the back (lower/mid back) according to randomization schedule and worn for 12 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Type 2 diabetes mellitus - HbA1c 7.0-10.0% \[53-86 mmol/mol\] (both inclusive) by central laboratory analysis - Current treatment with insulin glargine for at least 90 days prior to screening - Stable daily dose of insulin glargine between 20 units and 50 units (both inclusive) for at least 56 days prior to screening. Total daily dose should be within the range of 20-50 units, both inclusive, on the day of screening, but individual fluctuations of plus/minus 10 procent within the 56 days prior to screening are acceptable - Stable daily dose of metformin (above or equal to 1500 mg or max tolerated dose) for at least 90 days prior to screening - Body mass index (BMI) below or equal to 40 kg/m\^2 Exclusion Criteria: - Any use of oral antidiabetic agents (OADs) (except for metformin) within 90 days prior to Visit 1 (screening) - Current use of any drug (except metformin and insulin glargine) or anticipated change inconcomitant medication, which in the investigator's opinion could interfere with the glucose metabolism (e.g. systemic corticosteroids) - Previous and/or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness includinggestational diabetes is allowed at the discretion of the investigator) - Previous and/or current treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. exenatide, liraglutide) - Impaired liver function, defined as ALAT (alanine aminotransferase) above or equal to 2.5 times upper normal range (UNR) - Impaired renal function defined as serum-creatinine above or equal to 133 micromol/L (above or equal to 1.5 mg/dL) for males and above or equal to 125 micromol/L (1.4 mg/dL) for females, or as allowed according to local contraindications for metformin - Screening calcitonin above or equal to 50 ng/L - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) - History of chronic pancreatitis or idiopathic acute pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec/liraglutide OD plus metformin (Type: EXPERIMENTAL): None
- Insulin glargine OD plus metformin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigational Therapeutics for the Treatment of People With Ebola Virus Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Males or females of any age with documented positive RT-PCR in blood for acute Ebola virus infection within 3 days prior to enrollment and who have symptoms of any duration.~* Willingness of study participant to accept randomization to any assigned treatment arm.~* All males and females of childbearing potential must be willing to use effective methods of contraception, from time of enrollment until Day 58 of study.~* Must agree not to enroll in another study of an investigational agent prior to completion of Day 28 of study.~* Ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so.~EXCLUSION CRITIERA:~* Patients who, in the judgment of the investigator, will be unlikely or unable to comply with the requirements of this protocol through Day 28.~* Prior treatment with any investigational antiviral drug therapy against Ebola virus infection within 5 half-lives or 30 days, whichever is longer, prior to enrollment. (Patients who have received an experimental (or, in future, potentially a licensed) immunization against Ebola virus remain eligible.)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Remdesivir plus optimized Standard of Care (oSOC)
- B (Type: EXPERIMENTAL): MAb114 plus optimized Standard of Care (oSOC)
- C (Type: EXPERIMENTAL): REGN-EB3 plus optimized Standard of Care (oSOC)
- Control (Type: EXPERIMENTAL): Zmapp plus optimized Standard of Care (oSOC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject of any ethnic background of 12 years or older.~* Subject with mild or moderate facial acne vulgaris defined as an Investigator Global Assessment (IGA) score at 2 or 3 on a 0-4 scale.~* Subject with any skin phototype according to T.B. Fitzpatrick skin phototype definitions.~Exclusion Criteria:~* Subject with severe acne (IGA\>3) with nodules, cysts, scars or extra-facial lesions,~* Female subject who is pregnant, lactating or planning a pregnancy during the study,~* Subject susceptible to take a corticosteroid treatment during the study except inhaled or topic when needed to treat a condition outside the face,

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Benzaknen treatment regimen (Type: EXPERIMENTAL): Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete